Chammartin, F; Lodi, S; Logan, R; Ryom, L; Mocroft, A; Kirk, O; Monforte, AD; ... Bucher, HC; + view all Chammartin, F; Lodi, S; Logan, R; Ryom, L; Mocroft, A; Kirk, O; Monforte, AD; Reiss, P; Phillips, A; El-Sadr, W; Hatleberg, C; Pradier, C; Bonnet, F; Law, M; De Wit, S; Sabin, C; Lundgren, JD; Bucher, HC; - view fewer (2021) Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy A Multinational Prospective Cohort Study. Annals of Internal Medicine , 174 (6) pp. 768-776. 10.7326/M20-5226.

Text m20-5226.pdf - Published Version Access restricted to UCL open access staff Download (257kB)

Abstract

Background: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non–AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 x 109 cells/L. Consequences of delayed ART on risk for non–AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. Objective: To estimate the long-term risk difference for cancer with the immediate ART strategy. Design: Multinational prospective cohort study. Setting: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included HIV-positive persons from Europe, Australia, and the United States. Participants: 8318 HIV-positive persons with at least 1 measurement each of CD4 cell count and viral load while ARTnaive (study period, 2006 to 2016). Measurements: The parametric g-formula was used, with adjustment for baseline and time-dependent confounders (CD4 cell count and viral load), to assess the 10-year risk for non–AIDS-defining and AIDS-defining cancer of immediate versus deferred (at CD4 counts <350 and <500 x 109 cells/L) ART initiation strategies. Results: During 64 021 person-years of follow-up, 231 cases of non–AIDS-defining cancer and 272 of AIDS-defining cancer occurred among HIV-positive persons with a median age of 36 years (interquartile range, 29 to 43 years). With immediate ART, the 10-year risk for non–AIDS-defining cancer was 2.97% (95% CI, 2.37% to 3.50%) and that for AIDS-defining cancer was 2.50% (CI, 2.37% to 3.38%). Compared with immediate ART initiation, the 10-year absolute risk differences when deferring ART to CD4 counts less than 500 x 109 cells/L and less than 350 x 109 cells/L were 0.12 percentage point (CI, 0.01 to 0.26 percentage point) and 0.29 percentage point (CI, 0.03 to 0.73 percentage point), respectively, for non– AIDS-defining cancer and 0.32 percentage point (CI, 0.21 to 0.44 percentage point) and 1.00 percentage point (CI, 0.67 to 1.44 percentage points), respectively, for AIDS-defining cancer. Limitation: Potential residual confounding due to observational study design. Conclusion: In this young cohort, effects of immediate ART on 10-year risk for cancer were small, and further supportive data are needed for non–AIDS-defining cancer. Primary Funding Source: Highly Active Antiretroviral Therapy Oversight Committee.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item